Abstract. The receptors in the fundic mucosa that mediate gastrin stimulation of acid secretion have been studied. Synthetic human gastrin-17-I (G17) with a leucine substitution in the 15th position ([Leu'5] 
Introduction
In 1905, Edkins (1) first hypothesized the existence of an antral stimulant of acid secretion. With the discovery of histamine in the gastric mucosa and the recognition of its properties as a potent stimulant of acid secretion (2, 3) , the existence of an antral "gastrin" hormone became the subject of a controversy that continued for 60 yr. In 1964, Gregory and Tracy (4) established beyond doubt the existence of the hormone gastrin in the antral mucosa. Subsequent studies established that gastrin is a potent stimulant ofacid secretion; it has a major physiological role in mediating the acid secretory response to a protein meal (5, 6) . Gastrin also has several other actions, including contraction of antral smooth muscle (5) and a trophic effect on the fundic mucosa (7) .
Despite the evidence that gastrin is a major endogenous stimulant of acid secretion, uncertainty persists in regard to the locus of the receptor(s) that mediates the acid secretory actions of gastrin. Previous evidence showed that gastrin stimulates the function of parietal cells isolated from canine fundic mucosa (8, 9) and that these effects of gastrin are potentiated by interaction with histamine (10, 1 1). However, direct gastrin effects on parietal cells remain controversial. In the rabbit, gastrin has been reported to stimulate histamine release from gastric glands (12) and to cause only minimal, if any, direct stimulation of parietal cell function (13, 14) , which suggests that the rabbit gastrin receptors may be present on the histamine cell as well as, or rather than, on the parietal cell. To further complicate the histamine-gastrin relationship, the cell types storing histamine vary between species. In the rat fundic mucosa, histamine is present in an enterochromaffin-like cell (15) (16) (17) , whereas in canine (18) and human (19) fundic mucosa, current evidence indicates the presence of histamine only in mast cells. An additional difference is that gastrin stimulates the formation of histamine in the rat but not in canine fundic mucosa (15, 16) . These divergent findings underline the uncertainty regarding the cellular locus of receptors of gastrin in the fundic mucosa.
Biologically active radiolabeled ligands provide a powerful tool for the localization and characterization of receptors for chemical transmitters. Recently, Takeuchi et al. (20) have demonstrated a receptor for gastrin in a particulate fraction from homogenates of rat fundic mucosa, although the cellular locus of this receptor and its role in mediating a direct biological response to gastrin were not identified. These workers found that native heptadecapeptide gastrin iodinated by chloramine T did not retain biological activity (20) . This finding was at odds with a previous study that indicated that gastrin could be iodinated with preservation of biological activity (21) . This difference probably indicates that iodination of gastrin, unless carefully controlled, risks oxidative damage. However, Takeuchi et al. (20) found that when there was a leucine substitution for methionine in the 15th position ofgastrin-17 (G17),' iodination then yielded a biologically active product that demonstrated specific binding to rat gastric mucosa.
The present studies, using '251-synthetic human G17 with a leucine substitution in the 15th position (I251-[Leu']-G17) as a probe for the gastrin receptor, were aimed at localizing the gastrin receptor(s) on cells isolated from canine fundic mucosa and correlating receptor binding to a biological response to gastrin.
Methods
Cell dispersion and separation. Cells were dispersed from adult canine fundic mucosa by using techniques adapted from those previously described (8) . In brief, the fundic mucosa from dogs killed with a pentobarbital infusion was bluntly separated from the submucosa and then sequentially incubated in crude collagenase (0.25 mg/ml) and EDTA (1 mM). Cell separation was performed by using a elutriator rotor (Beckman Instruments, Inc., Fullerton, CA) (8, 22) . This technique separates cells on the basis of varying sedimentation velocity, which is proportional to the square of the cell radius. Fractions were collected according to the protocol outlined previously (22) .
Stepwise density gradients were formed by using a heavy solution of 24% bovine serum albumin (BSA) (Boehringer Mannheim, Indianapolis, IN) plus 9% Ficoll 400 (Pharmacia Fine Chemicals, Piscataway, NJ) dissolved in Hanks' balanced salt solution (Irvine Scientific, Irvine, CA) that had been diluted with water to 64% of the normal salt concentration. The light solution was composed of 12% BSA in Hanks' solution diluted with water to 87% of normal salt concentration. pH 1. Abbreviations used in this paper: AP, ['4C]aminopyrine; APR, AP accumulation ratio; CCK, cholecystokinin; CCK8, the carboxyl terminal octapeptide (26-33) of cholecystokinin; G14-17, the carboxyl terminal tetrapeptide common to gastrin and cholecystokinin; G17, synthetic human gastrin-17 I; [Leul5]-G07, synthetic human gastrin-17 I with a leucine substitution in the 15th position; K,, the dissociation constant for an inhibitor. was adjusted to 7.4 with 2 N NaOH (higher concentrations of NaOHprecipitated protein). These solutions were modified from those used previously for linear gradient separations ofcanine fundic mucosal mast cells (18) .2 Gradients were formed in 50-ml polypropylene test tubes with a peristaltic pump. The respective densities of the heavy and light solutions were p = 1.066 and p = 1.037. These solutions were mixed in ratios of 25% heavy/75% light for the upper gradient step and 65% heavy/35% light for the bottom step. Gradients were centrifuged in a Sorvall RC-5 at 430 g for 60 min at room temperature; a rate controller was used for acceleration and deceleration. Cell bands formed at the interfaces were removed by using a peristaltic pump and a capillary tube. [Leu'5] -G17, rather than the 3: 1 ratio previously described (2 1). Monoiodo-G 17 wasseparated from free iodine and the diiodo forms by using DEAE chromatography.
G17 and [Leu5]-G017 were also iodinated with 127I. The specific activity of the monoiodo '25I-[Leu'5]-G17 prepared by these techniques was -1.8 uCi/pmol. The chemical purity of the G17 and CCK8 peptides was verified by high pressure liquid chromatography, which was performed by Drs. J. Reeve and D. Abrahm using a Vydac CA reversephase column and eluting with increasing concentrations ofacetonitrile, by starting from a 0.1% trifluoroacetic acid solution. For both G17 and CCK8 used in these studies, >95% of the absorbance at 220 and 280 nm was associated with a single, sharp peak containing the immunoreactive peptide. For both G17 and CCK8, amino-acid analysis was consistent with the composition expected for the pure peptides and the quantities were within 85% of the values predicted from the amount of peptide analyzed.
For the study of gastrin binding, cells were suspended in Hanks' balanced salt solution, with 0.1% BSA, and 25 mM Hepes (CalbiochemBehring Corp., San Diego, CA) added. Binding studies were performed in 12 X 75-polystyrene tubes, with 50 ul of the tracer and 50 ,l of unlabeled hormones or buffer added while the tubes were on ice. Cells (1 to 2 X 106/ml in 0.9 ml) were then added and the tubes were incubated at 37°C for 30 min in a shaker bath at 100 oscillations per minute, unless otherwise noted. At the end of the incubation period, triplicate 0.25-ml samples were layered over 0.9 ml of Hanks' solution (with 0.1% BSA) in 1.5-ml polypropylene microfuge tubes and then centrifuged at 8,700 g for I min in a Beckman Instruments, Inc., microfuge B. The supernatant was aspirated; the tips were excised; and the cell pellets were counted in a gamma counter (Tracer, Chicago, IL) with an 88% efficiency rate. Cell suspensions were also counted to determine the total 2. It is important to check osmolality and density of the solutions used for the density separations. We determined osmolality of the Ficoll and BSA solutions by a vapor pressure osmometer and adjusted to 290 mosM by altering the concentrations of the Hanks' salts added. The osmolality achieved with different batches ofalbumin had varied, possibly due to differences in the amount ofcontaminating salts; and the formula for the density gradient solutions was thus modified from our previous report (18) .
125I-[LeuI5]-G17 present. Background radioactivity was routinely determined by counting tips excised from tubes that contained the tracer, but no cells; this value ranged from 60 to 110 cpm and was subtracted from the data. In each study the total binding of 10-30 pM 1251-[Leu15J-G17 and the binding of this tracer in the presence of 100 nM G17 or 1 MM pentagastrin (nonspecific or nonsaturable binding) was determined. Saturable binding, the difference between total and nonsaturable binding, was corrected for cell count as was determined by using an Electro Zone Celloscope (Particle Data, Inc., Elmhurst, IL) (8) . The 1251-[Leu'5]-G17 label was always used within 4 wk of preparation and significant deterioration of specific binding was not found during this time.
In preliminary studies, the binding of 1251-[Leu5]J-G17 was compared by using parietal cell-enriched fractions that were suspended in Earles balanced salt solutions and in the Hanks' medium described above. In three experiments, the specific 1251-[Leu'5]-GI7 binding was 7.23±1.72% (mean±SE) per 106 cells in Hanks' and 5.14±0.55% per 106 cells in the Earle's medium. Hanks' was chosen for further studies since its use did not require a CO2 gas phase. The effects of different washing steps on the binding were also studied. Using a cushion of 1.0 ml of 0.1% BSA produced backgrounds that were as low as those found with 10% BSA. Further washing steps after the first aspiration did not reduce the nonspecific binding enough to warrant the time required.
Aminopyrine accumulation. The accumulation of ['4C]aminopyrine (AP) was used as an index of parietal cell response to stimulation. AP accumulation ratio (APR) provides a quantitative index of parietal cell response to stimulation, which reflects the quantity of sequestered acid, but not the actual rate of acid secretion (9) . This technique has been adapted for study of isolated canine parietal cells (9) from the original method developed by Berglindh (23) for rabbit gastric glands. In brief, 0.1 MlCi of ['4Caminopyrine and the stimulants and inhibitors to be tested were added to fractions of enriched parietal cells suspended in 2 ml of Earle's or Hanks' balanced salt solution with 0.1% BSA and 10 mM Hepes added.3 Cells were incubated for 20 min and separated by centrifugation in a microfuge B (Beckman Instruments, Inc.), and radioactivity in the cell pellet was determined in a liquid scintillation counter. APR were calculated as the counts per minute per parietal cell volume divided by the concentration of radioactivity in the suspension, as previously described (9) . The AP data have been expressed as the percent maximal response over basal to the agents indicated in the legends. For the dose-response studies illustrated in Fig. 9 , the response to gastrin was studied with a background of histamine and data were expressed as the maximal response to gastrin over this histamine back- 7-10 d after transport seemed to considerably improve the consistency of the parietal cell response to stimulation. The emphasis in the present studies was evaluating dose-response relations, and we have excluded those preparations in which gastrin did not produce a twofold increase in AP accumulation above basal, and used all of the remaining data for analysis.
Data analysis. Tests of the statistical significance of differences were performed by using the t test; paired analyses were used when indicated. In studies of both gastrin binding and of AP accumulation, the means of triplicate determinations for one or two separate incubations for each treatment group have been used for subsequent analysis, with n equal to the number of separate cell preparations. Where mean values for data are given they are followed by ±SE of the mean (n = number of separate cell preparations).
Receptor-binding models (defined where subsequently used) were fit separately to the data from each dog studied, by using a nonlinear, least-squares computer program (BMDPAR, 24). Means and standard errors ofthe estimated dissociation constants were computed (n = number of dogs).
Results
Biological activity of iodinated gastrin. Initial studies used iodinated native G17, since this ligand had been shown to be biologically active (21) . Preliminary studies with some preparations ofthis label found significant saturable binding to fundic mucosal cells (25) ; however, other preparations oftracer showed no specific binding ( Fig. 1 B) . In contrast, iodination of [Leu'5]-G17 produced a ligand that had reproducibly high saturable binding to fractions enriched in canine parietal cells (Fig. 1 A) . Canine fundic mucosal cells were separated by elutriation into nine fractions by using a protocol previously described (22) . Stepwise density-gradient separation of enriched parietal and chief cell elutriator functions. Gradients were formed by varying the proportions of heavy and light solutions that were described in Methods. A 10-ml step of a 65% heavy solution was loaded first, followed by a similar volume step to a 25% heavy solution, with cells loaded in 30 ml of a 12% heavy solution. Stepwise density gradients were initially performed starting with elutriator fractions 6 and 7 (A) of fraction 8 (B). Two fractions were collected: fraction A banding above the 65% heavy step and fraction B that pelleted through this 65% heavy solution. The parietal cell and chief cell contents were determined counting slides prepared on a cytocentrifuge and stained with periodic acid Schiff (22) . and the chief cells enriched to 76 and 77%, respectively. In these other two gradients, correlation coefficients between gastrin binding and parietal cells content were 0.98 and 0.99 and the correlation coefficients for the relationship between gastrin binding and the chief cell distribution were both -0.99 (n = 6 for each pair of density-gradient separations). enriched in parietal cells. As indicated in Fig. 3 To further distinguish between gastrin binding to parietal cell and chief cells, stepwise density-gradient separations were performed on the chief cell-enriched fractions (fractions 6 and 7) and the parietal cell-enriched fraction (fraction 8). In the first three gradients performed with this technique, chief cells were enriched to 76-92%; and parietal cells, from 85 to 92%, respectively, in the more dense and less dense of the two steps collected (Fig. 4) . In more recent studies, by adjusting the osmolality of the solutions and refining the density steps, it has been possible to use a starting fraction that includes fractions 6-9 from the elutriator separation and to achieve enrichment of chief cells between 80 and 90% and parietal cells to >95%. In these stepwise density gradients there is a striking positive correlation between the parietal cell content ofthe fraction stud- 90 dilution. This protocol for TIME (MIN) studying dissociation did not include a wash step to remove tracer from the medium before the 100-fold dilution. We chose this protocol because it avoided the possibility of dissociation occurring during the wash step. Rebinding of tracer from the diluted medium may occur; however, this possibility seems unlikely since we did not detect binding to fresh cells with the tracer at a 100-fold dilution (data not illustrated). Also, such rebinding would be reduced when excess unlabeled hormone was added and we detected no differences with initiating dissociation by dilution and dilution plus excess unlabeled pentagastrin. '25I-[Leu'5]-G17 binding to the cells was determined. At 370C dissociation was rapid, with 50% of the label dissociating within 30 min (Fig. 7) . After 90 min of incubation, 20% of the initial counts remained bound to the cells. The addition of excess pentagastrin (1 MM) did not accelerate the rate of dissociation beyond that found with dilution alone (Fig. 7) . Reducing the temperature of incubation to 300C did not reveal any difference in the dissociation rate found with dilution or dilution plus the addition of pentagastrin at concentrations of 0.32 nM, 1 nM, and 1 qM (n = 2, data not shown).
Hormone degradation. (Fig. 2) . The data were fit by using a nonlinear, least-squares procedure that has statistical advantages compared with the Scatchard linearization (27) of this equation.4
4. The data in Fig. 8 have been fit to a one-receptor site equilibrium model for displacement binding by both nonlinear curve fitting of equation (1) with a computer program for least-square estimation and by a Scatchard plot (27). The Scatchard linearization has been derived in the Appendix. Although eq. 1 is algebraically equivalent to the Scatchard transformation, nonlinear curve fitting has advantages from a statistical point of view (28) . In a least-squares curve fit, the x variable is assumed to be measured (or fixed) without error. When points are not weighted, errors in measurement of y are assumed to be the same magnitude at each value of x, which is a reasonable condition for the present data (see Fig. 8 A) . In the Scatchard plot, errors appear in both x and y and the errors in estimating the total bound hormone are often very large when a low fraction of tracer is bound at high hormone concentrations (Fig. 8 B) . Such errors at low values of the bound to free ratio, B*/H?, can give the impression of a curvilinear or two-component plot (Fig. 8 B) . The Kd calculated for G17 was 4.64±0.71 X 10-' M (mean±SE, n= 12). This analysis indicated 24,100±3,100 (mean±SE, n = 12) gastrin receptor sites per cell in the parietal cell-enriched fraction. Assuming that parietal cells account for the detectable binding (Fig. 4) , this approach estimates 43,700±5,000 sites per parietal cell (mean±SE, n = 12). Displacement of '251-[Leu'5]-GI7 binding by CCK8, G17, and G14-17 was compared (Fig. 9 A) . CCK8 had a Kd of 2.71±0.50 X 10-' M (mean±SE, n = 12), and, thus, was slightly more potent than the G 17, although this difference was not statistically significant. G14-17 had a Kd of 4.1±0.9 X 10-8 M (mean±SE, n = 6), which reflected a potency much less than that for CCK8 or G17.
In parallel studies, stimulation of parietal cell AP accumulation was studied (Fig. 9 B) . To determine the Kd, we assumed the response, as reflected in the APR, to be directly proportional to receptor occupancy, and used this MichaelisMenton equation:
Ht +Kd (2) in which H, is the concentration of stimulant and Kd is the dissociation constant for the stimulant. This equation was separately fit to data from each dog. In a given cell preparation, the APRma,,. was constrained to be the same for all stimuli. G 17
x intercept, respectively, are subject to considerable error (Fig. 8 B) .
With the present availability of computers, nonlinear curve fitting with nontransformed data offers an attractive alternative to linearization (28) . (Fig. 9) . In these latter studies the 1( for GI 7 and CCK8 for inhibition of 125i-[Leul5]-G17 binding were 3.6±0.8 X 10-10 and 3.6± 1.0 X 10-10, respectively. Kd estimates for stimulation of AP accumulation were 2.1±0.3 X 10-10 and 3.7±0.8 X 10-10, respectively (mean±SE, n = 5). These values were much lower than the 1( for G14-17 of 1.2±0.6 X IO-' M (mean±SE, n = 4).
We did not find inhibition of 1251-[Leu'5]-G17 binding with histamine, cholinomimetics or their antagonists, or with several unrelated peptide hormones (Table II) . In contrast to the findings with gastrin receptors in rat gastric mucosa (20), we did not find displacement of '25I-[Leu'5]-G17 binding with secretin in concentrations between 0.1 and 100 nM (Table II) .
Gastrin receptor antagonist. Proglumide, a glutaramic acid derivative that antagonizes cholecystokinin (CCK) binding to pancreatic acinar cells (29) , inhibited the binding of'251-[Leu"5]-G17 to parietal cells (Fig. 10 A) . High concentrations of proglumide are required; 50% inhibition of the specific binding of the 20 pM '25I-[Leu"5]-G17 tracer occurred at a proglumide concentration of -1 mM. Proglumide at a concentration of 1 mM produced a surmountable rightward shift of the gastrin binding curve, although the effects of 3.2 mM proglumide were not clearly fully surmountable in the experiments performed (Fig. 10 A) .
Proglumide also inhibited gastrin stimulation ofparietal cell AP accumulation (Fig. 10 B) . Proglumide at a concentration of 1 The effects of the proglumide on AP accumulation stimulated by gastrin are illustrated, with these studies matched to those in (A). The AP accumulation has been expressed as the percentage of the response over basal found with I nM gastrin, which produced an AP accumulation ratio (9) in these four preparations of 15.5±3.5. concentration of 3.2 mM, however, appeared to inhibit basal AP accumulation, although this effect was surmounted at higher gastrin concentrations (Fig. 10 B) Proglumide specificity for the gastrin receptor was tested by examining the effects of proglumide on stimulation of parietal cell AP accumulation by histamine, dibutyryl cyclic AMP, and carbachol (Fig. 11) . Proglumide, in concentrations from 0.32 to 3.2 mM did not significantly decrease the response to histamine or dibutyryl cyclic AMP.' However, some inhibition of carbachol stimulation was found at the higher concentrations of proglumide (Fig. 1 1) . Proglumide inhibition of carbachol stimulation has been previously described in studies ofpancreatic acinar cells (28) .
Discussion
The present studies provide evidence that localizes '251-[Leu'5]-G17 receptors to canine parietal cells. The binding of 1251-[Leu'5]-G17 to these receptors displayed typical patterns for peptide hormone receptors; binding was rapid, reversible, and specific.
After a 30-min, 370C incubation with 251I-[Leu'5]-G17, 80% of the bound tracer dissociated within 90 min after 100-fold dilution; this finding makes it unlikely that the tracer-receptor complex is rapidly internalized into parietal cells. We found no evidence for negative cooperativity between gastrin receptor binding sites. In the presence of these receptor site-site interactions, receptor affinity will vary inversely with the fraction of receptors occupied; thus dissociation rate will increase as a function ofthe unlabeled hormone concentration (30) . In our present studies, adding pentagastrin to partially or completely saturated receptors did not accelerate the dissociation rate of tracer beyond 5. Proglumide at 3.2 mM appeared to potentiate the effects of 10 ,M histamine, although this effect was not statistically significant in the preparations tested. Proglumide may be a partial agonist and activate the parietal cell under certain conditions, such as the presence of the potentiating stimulant, histamine. A similar phenomenon has been noted with high concentrations of cimetidine (9). Ki values for these effects in the same order of magnitude (1.4 X l0-4 and 5.0 X l0-4 M, respectively).
Since the octapeptide of cholecystokinin and G17 were equally potent, the present data raise the question of whether the gastrin receptor on the isolated canine parietal cell is a CCK or a gastrin receptor. Furthermore, proglumide, which we found to interact specifically with the gastrin receptors on canine parietal cells, also interacts with the CCK receptor on pancreatic acinar cells (29) . The present results add further support to the view that, just as there is a family of CCK-gastrin peptides, there is also a family of related cell surface receptors for CCK and gastrin. This family of receptors includes a receptor on the pancreatic acinar cell that has a much higher affinity for CCK than G17 (32, 33) , a receptor in the brain that has a moderate preference for CCK over G17 (34, 35) , and the canine parietal cell receptor that has an equal affinity for CCK8 and G17. Antral smooth muscle cell responses to gastrin and CCK also indicate the presence of a receptor with equal affinity for gastrin and CCK (36) .
There have been several previous radioligand studies of gastrin receptor binding with antral smooth muscle homogenates, particulate and plasma membrane-enriched fractions of rat fundic mucosa, and isolated rat and rabbit fundic mucosal cells (20, (37) (38) (39) (40) . Two of these studies have established that the 1251I gastrin tracer used was biologically active, by interacting with a specific receptor (20, 40) . Our present work extends these previous studies by localizing the (42) . In vivo, pentagastrin is found to stimulate pepsin secretion, although the effect is modest compared with cholinergic stimulation (43, 44) . Furthermore, pentagastrin stimulation of pepsin output may only occur in innervated mucosa (44) and is totally blocked by anticholinergic agents (43) , raising the question as to whether pentagastrin acts directly on chief cell receptors. In contrast to these findings with pentagastrin, CCK stimulates pepsin secretion in both rabbit gastric glands (45) and canine chief cells (42) . These contrasting data suggest the possibility that chief cells have a receptor with a much higher affinity for CCK than for gastrin, similar to the CCK receptor on pancreatic acinar cells. Our present studies with a G17 tracer do not adequately test this hypothesis. An important question pertains to the other cellular loci of gastrin receptors in the fundic mucosa. Our present cell separation studies using the elutriator rotor indicate that gastrin receptors are present on a population of small mucosal cells, in addition to the much larger parietal cell. Cells containing somatostatin-like immunoreactivity are present in these small cell fractions and by studying short-term cultures of these fractions we have found that gastrin stimulates somatostatin release (Soll, A. H., J. Park, L. P. Thomas, and T. Yamada, submitted for publication). Thus, we conclude that at least one of the additional gastrin receptors in the canine fundic mucosa is present on the somatostatin cell, although the physiological significance of these receptors remains uncertain. Whether gastrin receptors also exist on any additional cells also remains an open question.
Although the present data indicate that the parietal cell accounts for the major proportion ofgastrin receptors in the canine fundic mucosa, it may not be possible to generalize this conclusion to all other species. As noted in the introduction, gastrin has been demonstrated to increase histamine formation in the rat, a species in which fundic mucosal histamine is stored in endocrine-like cells, but not in the dog, a species in which fundic mucosal histamine is stored in mast cells. With these differences in cell type and function, differences in gastrin receptor localization are also possible. Further studies will be necessary to determine the presence and physiological relevance of the gastrin receptor on different cell types in different species.,
The present reductionistic approach examines the individual pieces in order to learn about functioning of the whole and may at times appear only to add to the apparent complexity of the subject. Our present finding that CCK8 stimulates the isolated canine parietal cell with a potency and efficacy equal to that of GI 7 agrees with the observation that CCK is a full agonist of gastric acid secretion in vivo in the cat (46) . However, in the dog, CCK weakly stimulates acid secretion (47) . Thus, either the isolated canine parietal cell has very limited usefulness as a model for exploring physiologic mechanisms, or there are cellular elements involved in the response of the fundic mucosa to gastrin and CCK in addition to the parietal cell itself. Studies of the regulation of somatostatin cell function support the latter conclusion since CCK8 was found to be a much more effective stimulant of somatostatin release than was gastrin (48) . Thus, despite being equally potent to GI 7 in stimulating parietal cell function, CCK8 may not be a full agonist of acid secretion in vivo in the dog because of potent activation of inhibitory mechanisms mediated by somatostatin. This explanation for the contradictory actions of CCK in vitro of parietal cells and in vivo on acid secretion remains speculative. These mechanisms require a great deal of study, but we suggest that two concepts may be useful: (a) receptors for regulatory peptides, such as gastrin, will be present on more than one target cell in the fundic mucosa; and (b) differences in the specificity of receptor subtypes for such peptides may be an important factor in integrating the overall functional response.
hormone by total hormone introduces only a small risk of error since only -7% of total hormone is bound.
